June 2018 ExCERpts

Campaign Preview  HTML Source  Plain-Text Email  Details

View this email in your browser

June 2018

- GPC Project Launch: coreNASH
- coreHEM Team Focuses on Multi-Stakeholder Partnership at HTAi Conference
- Recent Staff Publications
- We're Hiring

GPC Project Launch: coreNASH
The Green Park Collaborative (GPC) is partnering with The Forum for Collaborative Research and the Obesity Action Coalition (OAC), to develop a core set of outcomes for non-alcoholic steatohepatitis (NASH). This initiative, coreNASH, will be conducted as a collaboration involving a multi-stakeholder team, including NASH patients, clinicians, payers, health technology assessment groups, regulators, life sciences companies and others, who will help establish a consistent and stakeholder-relevant baseline for evaluation of NASH therapies.

Read More

coreHEM Team Focuses on Multi-Stakeholder Partnership at HTAi

The coreHEM team presented a 75-minute panel session at the HTAi Annual Meeting in Vancouver, British Columbia on June 3rd, 2018. The 6-person panel demonstrated the multi-stakeholder collaboration used to rapidly develop a core outcome set to be used in for gene therapy in hemophilia. The panel, entitled “Core Outcome Sets and HTA: coreHEM Defining Value Through Multi-Stakeholder Engagement,” was moderated by CMTP’s Sean Tunis, who is currently serving as president of HTAi.

CMTP’s Elizabeth Clearfield provided an overview of the methods and results, and then each panel member spoke about the project from their stakeholder perspective. Alfonso Iorio of McMaster University gave a methodological and clinical perspective and reported how novel outcomes will be important for measuring new gene therapy technology. Sophie Werkö of SBU, the Swedish HTA agency, provided insight on why it is important for HTA groups to be involved in core outcome set projects. Mohit Jain of BioMarin Pharmaceuticals summarized the response from the life science industry participants, highlighting how the process can help participants understand the informational needs for decision-makers. Edmund Pezalla, of enlightenment bioconsult, spoke of the payer perspective and how to ensure relevance to patients.
spoke of the payer perspective and how to assure relevance to payers by considering together the clinical benefits, the non-clinical benefits, the health system benefits and the societal benefits of a new treatment. **Mark Skinner**, representing the National Hemophilia Foundation, rounded out the panel by detailing the importance of patient-focused drug development and demonstrating how core outcomes can be used across the life cycle of a product.

Audience questions showed support for the project and confirmed applicability across the HTA landscape. coreHEM was featured again the following day in poster format. The poster, “HTA Role in coreHEM, a Multi-Stakeholder Core Outcome Set Project” was featured in the category “Stakeholder Involvement in HTA – Patient Involvement.”

Mark Skinner (National Hemophilia Foundation) and Elizabeth Clearfield (CMTP) with coreHEM poster "HTA Role in coreHEM, a Multi-Stakeholder Core Outcome Set Project" at the 2018 HTAi Annual Meeting.

Additional Information on coreHEM

Recent Staff Publications

Recent Publications from CMTP Staff (in bold below)
Insurance Coverage for Genomic Tests

Core outcome set for gene therapy in haemophilia: Results of the coreHEM multistakeholder project
Iorio A, Skinner MW, Clearfield E, Messner D, Pierce GF, Witkop M, Tunis S; for the coreHEM panel. Core outcome set for gene therapy in haemophilia: Results of the coreHEM multistakeholder project. Haemophilia. 2018;00:1–6. https://doi.org/10.1111/hae.13504

We're Hiring
We're currently seeking a Research Director. The Research Director will conceptualize, plan, implement, monitor, and coordinate projects consistent with CMTP’s mission, and relevant especially to CMTP’s program areas of Green Park Collaborative and Scientific Advice, plus other areas as needed. See job description for submission instructions.
Our mailing address is:
Center for Medical Technology Policy
401 E Pratt Street
Suite 631
Baltimore, MD 21202

Add us to your address book

Want to change how you receive these emails?
You can update your preferences or unsubscribe from this list